Remission of acromegaly caused by pituitary carcinoma after surgical excision of growth hormone-secreting metastasis detected by 111-indium pentetreotide scan.

GH-secreting carcinomas of the pituitary are extremely rare. We describe a 37-yr-old woman with refractory acromegaly 15 yr after transphenoidal surgery and radiotherapy, with no evidence of a recurrent pituitary mass. Scanning with 111-indium pentetreotide revealed an area of intense activity in the left neck. A 3.5 x 2.5-cm mass was excised from the neck after demonstrating an arterio-venous GH gradient of 7:1. GH levels (50 ng/mL) dropped to 0.8 ng/mL 3 h after surgery and remained normal. GH gene expression was demonstrated in the metastasis by Northern and Western blot analyses and by positive immunocytochemistry and immunoelectron microscopy. In vitro cultured cells responded to GHRH and TRH by increasing GH levels (P < 0.01). Medium GH was identical to authentic pituitary GH, as demonstrated by high pressure liquid chromatography. RT-PCR of hypothalamic hormone receptor messenger RNA in the mass revealed somatostatin receptor subtypes 2, 3, and 5 and GHRH, TRH, and dopamine receptor expression. No GH gene amplification, rearrangement, or gsp mutation was found. RB gene deletion and H-ras mutations, previously reported in PRL- and ACTH-secreting carcinomas, were not detected. In conclusion, clinical and molecular features of a GH-secreting pituitary carcinoma are presented. This metastatic lesion synthesized GH and expressed functional hypothalamic hormone receptors.

[1]  B. Scheithauer,et al.  Frequent loss of heterozygosity at the retinoblastoma susceptibility gene (RB) locus in aggressive pituitary tumors: evidence for a chromosome 13 tumor suppressor gene other than RB. , 1995, Cancer research.

[2]  T. Miller,et al.  Fine‐needle aspiration biopsy of pituitary carcinoma with cervical lymph node metastases: A report of two cases and review of the literature , 1994, Diagnostic cytopathology.

[3]  E. Laws,et al.  Estrogen receptor expression in human pituitary: correlation with immunohistochemistry in normal tissue, and immunohistochemistry and morphology in macroadenomas. , 1994, The Journal of clinical endocrinology and metabolism.

[4]  B. Scheithauer,et al.  H-ras mutations in human pituitary carcinoma metastases. , 1994, The Journal of clinical endocrinology and metabolism.

[5]  S. Melmed,et al.  Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors. , 1994, The Journal of clinical endocrinology and metabolism.

[6]  R. Fahlbusch,et al.  In situ hybridization study of estrogen receptor messenger ribonucleic acid in human adenohypophysial cells and pituitary adenomas. , 1994, The Journal of clinical endocrinology and metabolism.

[7]  G. Bell,et al.  Cloned somatostatin receptors: identification of subtype-selective peptides and demonstration of high affinity binding of linear peptides. , 1993, Molecular pharmacology.

[8]  S. Nagataki,et al.  Acromegaly and Pituitary Carcinoma , 1992, Annals of Internal Medicine.

[9]  D. London,et al.  Growth hormone secreting pituitary carcinoma: a case report and literature review , 1992, Clinical endocrinology.

[10]  E. Hedley‐Whyte,et al.  Ras mutations in human pituitary tumors. , 1992, The Journal of clinical endocrinology and metabolism.

[11]  S. Mather,et al.  Pituitary imaging using a labelled somatostatin analogue in acromegaly , 1992, Clinical endocrinology.

[12]  E. Krenning,et al.  The role of somatostatin and its analogs in the diagnosis and treatment of tumors. , 1991, Endocrine reviews.

[13]  S. Melmed,et al.  Hypothalamic hormonal regulation of human growth hormone gene expression in somatotroph adenoma cell cultures , 1990, Endocrine Pathology.

[14]  H. Bourne,et al.  GTPase inhibiting mutations activate the α chain of Gs and stimulate adenylyl cyclase in human pituitary tumours , 1989, Nature.

[15]  R. Mayfield,et al.  Pituitary adenocarcinoma in an acromegalic patient: response to bromocriptine and pituitary testing: a review of the literature on 36 cases of pituitary carcinoma. , 1989, The American journal of the medical sciences.

[16]  K. Takakura,et al.  Malignant growth hormone-secreting pituitary adenoma with hematogenous dural metastasis: case report. , 1988, Neurosurgery.

[17]  J. Said,et al.  Detection of estrogen receptors with monoclonal antibodies in routinely processed formalin-fixed paraffin sections of breast carcinoma. Use of DNase pretreatment to enhance sensitivity of the reaction. , 1987, American journal of clinical pathology.

[18]  H. Handa,et al.  Intracranial and intraspinal dissemination from a growth hormone-secreting pituitary tumor. Case report. , 1986, Journal of neurosurgery.

[19]  M. Molitch Pregnancy and the hyperprolactinemic woman. , 1985, The New England journal of medicine.

[20]  K. Kovacs,et al.  Acromegaly due to secretion of growth hormone by an ectopic pancreatic islet-cell tumor. , 1985, The New England journal of medicine.

[21]  E. Krenning,et al.  Regulation of hormone release by cultured cells from a thyrotropin-growth hormone-secreting pituitary tumor. Direct inhibiting effects of 3, 5, 3′-triiodothyronine and dexamethasone on thyrotropin secretion , 1984, Journal of endocrinological investigation.

[22]  W. Rutter,et al.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. , 1979, Biochemistry.

[23]  J. Jakubowski,et al.  Intracranial dissemination of pituitary adenomas , 1973, Journal of neurology, neurosurgery, and psychiatry.

[24]  T. H. Newton,et al.  Primary carcinoma of the pituitary. , 1962, The American journal of roentgenology, radium therapy, and nuclear medicine.